SiRNA for inhibiting AURKA gene expression and conjugate and application thereof
Patent Information
- Application Number
- CN202411101246.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-19
AI Technical Summary
[0005]然而,能否将RNA干扰用于SCLC治疗是未知的,以及其在SCLC中的作用机理亦是不明晰的
[0064] The siRNA, pharmaceutical composition and siRNA conjugate provided by the present invention have significantly enhanced inhibitory properties on the proliferation of NCI-H446 cells, also have higher AURKA mRNA inhibitory activity, and/or can significantly treat small cell lung cancer and /or illness. The siRNA, pharmaceutical composition or siRNA conjugate provided by the present invention shows excellent target gene inhibition activity in in vitro experiments. Therefore, the siRNA, pharmaceutical composition and siRNA conjugate provided by the present invention can inhibit the expression of the cell AURKA gene, effectively treat small cell lung cancer, and have good application prospects.
Smart Images

Figure CN118979037A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to siRNA for inhibiting AURKA gene expression and its conjugate and use, belonging to the field of biomedicine. Background Art
[0002] Lung cancer can be roughly divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which small cell lung cancer accounts for about 15-20% of all lung cancers. Small cell lung cancer is highly malignant and progresses rapidly. Distal metastasis may occur soon after onset. Some patients only live 3-6 months from diagnosis to death, and the 5-year survival rate is only about 5%. SCLC accounts for about 15% of the total number of lung cancers. It can be divided into two categories: limited stage (LS-SCLC) and extensive stage (ES-SCLC). Limited stage means that the cancer is limited to one lung and may exist in the lymph nodes on the same side of the chest. If the cancer spreads to the other lung, the lymph nodes on the other side of the chest, or distant organs, it is called extensive stage. Most patients are already in the extensive stage or the limited stage that cannot be removed when diagnosed, and few patients can be cured by surgery. Regardless of the stage of the patient, systemic platinum-based chemotherapy is the main treatment for SCLC. Although SCLC is very sensitive to platinum-based chemotherapy and the patient remission rate can reach 50%-90%, disease recurrence and rapid progression are very common. Therefore, there is currently no specific drug for the treatment of SCLC.
[0003] Inactivation of both tumor suppressors, p53 and RB (encoded by TP53 and RB1, respectively), was found in the vast majority of SCLC cases. RB is a tumor suppressor gene with a mutation rate of over 90% in small cell lung cancer (SCLC) cells. Nearly 60% of patients with SCLC, whose five-year survival rate is less than 10%, have RB gene deletions. The microtubule protein stathmin is highly upregulated in RB1-deficient cells, inducing unbalanced microtubule dynamics. AURKA is a microtubule destabilizer and a substrate for AURKA-inhibited phosphorylation. Therefore, inhibition of AURKA activity can activate stathmin, which strongly promotes microtubule depolymerization in RB1-deficient tumor cells, thereby severely affecting spindle formation and triggering mitotic cell death.
[0004] RNA interference (RNAi) refers to a gene silencing phenomenon induced by double-stranded RNA in molecular biology. Its mechanism is to inhibit gene expression by hindering the transcription or translation of specific genes. When double-stranded RNA homologous to the coding region of endogenous messenger RNA (mRNA) is introduced into cells, the mRNA is degraded and gene expression is silenced. Small interfering RNA (siRNA) with a length of 20-25nt can trigger RNAi, which can specifically downregulate or shut down the expression of specific genes. It has the characteristics of high efficiency, easy synthesis and easy operation, so this technology has been widely used in the field of exploring gene function and gene therapy for infectious diseases and malignant tumors.
[0005] However, it is unknown whether RNA interference can be used to treat SCLC, and its mechanism of action in SCLC is also unclear. Therefore, it is urgent to use RNA interference technology to achieve effective relief and treatment of SCLC. Summary of the invention
[0006] In view of the deficiencies in the prior art, the present invention provides siRNA for inhibiting the expression of the AURKA gene and its conjugates and uses, with the aim of designing corresponding siRNA for AURKA, which can effectively reduce the expression of AURKA protein by interfering with the AURKA mRNA of tumor cells, and cause the death of tumor cells with RB1 gene deletion or inactivation through synthetic lethal effect, thereby playing a role in treating tumors.
[0007] The first technical solution provided by the present invention is an siRNA for inhibiting the expression of the AURKA gene, wherein the siRNA contains a sense strand and an antisense strand, and each nucleotide in the siRNA is independently a modified or unmodified nucleotide, wherein the sense strand contains a nucleotide sequence I, and the antisense strand contains a nucleotide sequence II, and the nucleotide sequence I and the nucleotide sequence II are at least partially reverse-complemented to form a double-stranded region, and the nucleotide sequence I and the nucleotide sequence II are selected from any one of the following sequences (a) to (n):
[0008] (a) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.1, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.16, and optionally has no more than 3 nucleotide differences:
[0009] SEQ ID NO.1: 5'-CAGCAAUUUCCUUGUCAGAAU-3';
[0010] SEQ ID NO.16: 5'-UCUGACAGGAAAUUGCUGAG-3';
[0011] (b) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.2, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.17, and optionally has no more than 3 nucleotide differences:
[0012] SEQ ID NO.2: 5'-GGCUUUGGAAGACUUUGAA-3';
[0013] SEQ ID NO.17: 5'-UUCAAAGUCUUCCAAAGCC-3';
[0014] (c) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.3, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.18, and optionally has no more than 3 nucleotide differences:
[0015] SEQ ID NO.3: 5'-AGGAAAGUUUGGUAAUGUUUA-3';
[0016] SEQ ID NO.18: 5'-AACAUUACCAAACUUUCCUUU-3';
[0017] (d) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.4, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.19, and optionally has no more than 3 nucleotide differences:
[0018] SEQ ID NO.4: 5'-GAAAGUUUGGUAAUGUUUAUU-3';
[0019] SEQ ID NO.19: 5'-UAAACAUUACCAAACUUUCCU-3';
[0020] (e) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.5, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.20, and optionally has no more than 3 nucleotide differences:
[0021] SEQ ID NO.5: 5'-GGAGUGGAGCAUCAGCUCAGA-3';
[0022] SEQ ID NO.20: 5'-UGAGCUGAUGCUCCACUCCGG-3';
[0023] (f) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.6, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.21, and optionally has no more than 3 nucleotide differences:
[0024] SEQ ID NO.6: 5'-GCAUCAGCUCAGAAGAGAAGU-3';
[0025] SEQ ID NO.21: 5'-UUCUCUUCUGAGCUGAUGCUC-3';
[0026] (g) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.7, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.22, and optionally has no more than 3 nucleotide differences:
[0027] SEQ ID NO.7: 5'-GAGUCUACCUAAUUCUGGAAU-3';
[0028] SEQ ID NO.22: 5'-UCCAGAAUUAGGUAGACUCUG-3';
[0029] (h) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.8, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.23, and optionally has no more than 3 nucleotide differences:
[0030] SEQ ID NO.8: 5'-AAGUUUGAUGAGCAGAGAACU-3';
[0031] SEQ ID NO.23: 5'-UUCUCUGCUCAUCAAACUUUG-3';
[0032] (i) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.9, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.24, and optionally has no more than 3 nucleotide differences:
[0033] SEQ ID NO.9: 5'-GAUGAGCAGAGAACUGCUACU-3';
[0034] SEQ ID NO.24: 5'-UAGCAGUUCUCUGCUCAUCAA-3';
[0035] (j) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.10, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.25, and optionally has no more than 3 nucleotide differences:
[0036] SEQ ID NO.10: 5'-UGUCAUUCGAAGAGAGUUAUU-3';
[0037] SEQ ID NO.25: 5'-UAACUCUCUUCGAAUGACAGU-3';
[0038] (k) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.11, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.26, and optionally has no more than 3 nucleotide differences:
[0039] SEQ ID NO.11: 5'-AGUUAUUCAUAGAGACAUUAA-3';
[0040] SEQ ID NO.26: 5'-AAUGUCUCUAUGAAUAACUCU-3';
[0041] (1) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.12, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.27, and optionally has no more than 3 nucleotide differences:
[0042] SEQ ID NO.12: 5'-UCAAGACUGUUGAAGCAUAAU-3';
[0043] SEQ ID NO.27: 5'-UAUGCUUCAACAGUCUUGAAA-3';
[0044] (m) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.13, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.28, and optionally has no more than 3 nucleotide differences:
[0045] SEQ ID NO.13: 5'-UAAAGCUGUUGGAAUGAGUAUGUGA-3';
[0046] SEQ ID NO.28: 5'-UCACAUACUCAUUCCAACAGCUUUACC-3';
[0047] (n) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.14, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.29, and optionally has no more than 3 nucleotide differences:
[0048] SEQ ID NO.14: 5'-GUGAUUCUUUUUAAGUAUGAAAAUA-3';
[0049] SEQ ID NO. 29: 5'-UAUUUUCAUACUUAAAAAGAAUCACAU-3'.
[0050] In one embodiment, at least one nucleotide in the sense strand or the antisense strand is a modified nucleotide.
[0051] Furthermore, at least one nucleotide in the sense strand or the antisense strand is a nucleotide or a nucleotide analogue in which the hydroxyl group at the 2' position of the ribose group is modified.
[0052] Further, the nucleotide in which the hydroxyl group at the 2' position of the ribose group is modified is selected from a nucleotide modified with 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, T-deoxy-2'-fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-ODMAP), T-O-dimethylaminoethoxyethyl (2'-O-DMAEOE) or 2'-ON-methylacetamide (2'-O-NMA).
[0053] Furthermore, the nucleotide analogue is one of isonucleotide, LNA, ENA, cET BNA, UNA and GNA.
[0054] In one embodiment, at least one phosphate group in the sense strand or the antisense strand is a phosphate group having a modified group.
[0055] Furthermore, the phosphate group having a modified group is a thiophosphate group formed by replacing at least one oxygen atom in the phosphodiester bond in the phosphate group with a sulfur atom.
[0056] In one embodiment, the siRNA is selected from the following table:
[0057]
[0058] Among them, the lowercase letter m indicates that the ribose group of a nucleotide on the right side of the letter is 2'-methoxyribose; the lowercase letter s indicates that the phosphate groups between the deoxyribonucleotides on both sides of the letter are thiophosphate groups; the lowercase letter f indicates that the ribose group of a nucleotide on the right side of the letter is 2'-O-ribose fluoride-modified.
[0059] The second technical solution provided by the present invention is an siRNA conjugate, which contains the siRNA described in the first technical solution and a conjugated group conjugated to the siRNA; the conjugated group includes a pharmaceutically acceptable targeting group and a linker, and the siRNA, the linker and the targeting group are covalently or non-covalently linked in sequence.
[0060] The third technical solution provided by the present invention is a pharmaceutical composition comprising the siRNA described in the first technical solution and / or the siRNA conjugate described in the second technical solution and a pharmaceutically acceptable carrier.
[0061] The fourth technical solution provided by the present invention is the use of the siRNA described in the first technical solution, or the siRNA conjugate described in the second technical solution, or the pharmaceutical composition described in the third technical solution in the preparation of a drug for treating a disease caused by AURKA gene expression.
[0062] The fifth technical solution provided by the present invention is the use of the siRNA described in the first technical solution, or the siRNA conjugate described in the second technical solution, or the pharmaceutical composition described in the third technical solution in the preparation of a drug for alleviating and / or treating small cell lung cancer.
[0063] The technical effects of the present invention are as follows:
[0064] The siRNA, pharmaceutical composition and siRNA conjugate provided by the present invention have significantly enhanced inhibition of proliferation of NCI-H446 cells, and also have high AURKA mRNA inhibitory activity, and / or can significantly treat diseases and / or conditions of small cell lung cancer. The siRNA, pharmaceutical composition or siRNA conjugate provided by the present invention shows excellent target gene inhibitory activity in in vitro experiments. Therefore, the siRNA, pharmaceutical composition and siRNA conjugate provided by the present invention can inhibit the expression of the AURKA gene, effectively treat small cell lung cancer, and have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0065] Figure 1 This is a diagram of the target gene knockdown activity of the modified sequence of Example 3 of the present invention.
[0066] Figure 2 This is a diagram of the target gene knockdown activity of the modified sequence of Example 4 of the present invention.
[0067] Figure 3 This is a diagram of the target gene knockdown activity of the modified sequence of Example 4 of the present invention.
[0068] Figure 4 This is a diagram of the target gene knockdown activity of the modified sequence of Example 5 of the present invention.
[0069] Figure 5 This is a graph of the IC50 of the sequence of Example 6 of the present invention. DETAILED DESCRIPTION
[0070] The preferred embodiments of the present invention are described below. It should be understood that the embodiments are for better explaining the present invention and are not used to limit the present invention.
[0071] The term "linked" as used herein, when referring to the connection between two molecules, means that the two molecules are connected by a covalent bond or the two molecules are associated via a non-covalent bond (eg, a hydrogen bond or an ionic bond).
[0072] "Oligonucleotide" of the present invention is a nucleotide sequence containing 10-50 nucleotides or nucleotide base pairs. In some embodiments of the present invention, the oligonucleotide has such a core base sequence, which is at least partially complementary to the coding sequence in the target gene expressed in the cell. The nucleotides can be optionally modified. In some embodiments of the present invention, after the oligonucleotide is delivered to the cell expressing the gene, the oligonucleotide can inhibit or block the expression of the gene in vitro or in vivo.
[0073] The term "inhibit" as used herein, when referring to the expression of a given gene, means that gene expression is reduced when the cell, cell population or tissue is treated with the siRNA, pharmaceutical composition and siRNA conjugate of the present invention, compared to cells, cell populations or tissues that have not been treated.
[0074] The term "inhibit" in the present invention is used interchangeably with "reduce", "silence", "downregulate", "suppress" and other similar terms, and includes any level of inhibition. Preferably, inhibition includes statistically significant inhibition or clinically significant inhibition.
[0075] Each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide. In the context of the present invention, unless otherwise specified, "conjugation" refers to the covalent connection between two or more chemical moieties each having a specific function; accordingly, "conjugate" refers to a compound formed by covalent connection between the chemical moieties. Further, "siRNA conjugate" refers to a compound formed by covalently connecting one or more chemical moieties having a specific function to siRNA.
[0076] In the above and below, unless otherwise specified, generally, "G", "C", "A", "T" and "U" represent nucleotides containing guanine, cytosine, adenine, thymine and uracil as bases, respectively. However, it should be understood that the term "ribonucleotide" or "nucleotide" may also refer to modified nucleotides, nucleotide analogs (surrogate replacement moieties) as described in further detail below.
[0077] In the context of the present invention, the expressions "complementary" or "reverse complementary" are used interchangeably and have the meaning known to those skilled in the art, i.e., in a double-stranded nucleic acid molecule, the bases of one chain are each paired with the bases on the other chain in a complementary manner. In DNA, the purine base adenine (A) is always paired with the pyrimidine base thymine (T) (or uracil (U) in RNA); the purine base guanine (C) is always paired with the pyrimidine base cytosine (G). Each base pair includes a purine and a pyrimidine. When adenine on one chain is always paired with thymine (or uracil) on the other chain, and guanine is always paired with cytosine, the two chains are considered to be complementary to each other, and the sequence of the chain can be inferred from the sequence of its complementary chain. Correspondingly, "mismatch" means in the art that in a double-stranded nucleic acid, the bases at corresponding positions are not paired in a complementary form.
[0078] In the above and below, unless otherwise specified, "substantially reverse complementary" means that there are no more than 3 base mismatches between the two nucleotide sequences involved; "substantially reverse complementary" means that there are no more than 1 base mismatch between the two nucleotide sequences; "completely reverse complementary" means that there is no base mismatch between the two nucleotide sequences. In the above and below, the existence of "nucleotide difference" between one nucleotide sequence and another nucleotide sequence means that the base type of the nucleotide at the same position of the former is changed compared with the latter. For example, when a nucleotide base in the latter is A, and the corresponding nucleotide base at the same position of the former is U, C, G or T, it is determined that there is a nucleotide difference at that position between the two nucleotide sequences. In some embodiments, when a nucleotide at the original position is replaced by an abasic nucleotide or its equivalent, it can also be considered that a nucleotide difference has occurred at that position.
[0079] As used herein, "treatment" refers to an approach to obtaining beneficial or desired results, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. In addition, a therapeutic benefit is obtained by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, although the subject may still be afflicted with the underlying disorder.
[0080] Example 1 Design of siRNA
[0081] A set of siRNAs targeting the human AURKA gene (human: NCBI refseqID NM_001323303.2) was designed based on the transcriptome sequence: including 110 pairs of unmodified siRNAs (as shown in Table 1), after homology alignment, the sequences that matched 100% with the cynomolgus monkey transcriptome were selected, and finally 14 pairs of unmodified siRNAs were retained. The details of the 14 pairs of unmodified AURKA sense and antisense strand nucleotide sequences are listed in Table 2. The details of the modified AURKA sense and antisense strand nucleotide sequences are listed in Table 3.
[0082] Table 1
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091] The underlined nucleotides in Table 1 are overhangs.
[0092] Table 2
[0093]
[0094]
[0095]
[0096] The underlined nucleotides in Table 2 are overhangs. NC is a pair of industry-recognized nonsense sequences that do not have a 100% match with the mRNA of any gene, so it is used as a negative control for siRNA transfection.
[0097] Table 3
[0098]
[0099] The abbreviations of the nucleotide monomers in Table 3 are shown in Table 4.
[0100] Table 4
[0101]
[0102]
[0103] Example 2 Preparation of siRNA
[0104] All siRNA sequences used in Example 1 were commissioned to be synthesized by Suzhou Ouli Biopharmaceutical Technology Co., Ltd.
[0105] Example 3 In vitro experiment on human bladder cancer cell J82
[0106] The specific steps are as follows:
[0107] 1) Human bladder cancer cells J82 (purchased from the cell bank of Kunming Institute of Chinese Academy of Sciences) in the logarithmic growth phase were digested with trypsin, and then digestion was terminated with complete medium supplemented with 10% FBS. The cells were collected by centrifugation, resuspended with medium supplemented with 10% FBS, counted with a hemocytometer, and then 30,000 cells were added to each well of a 24-well plate for culture.
[0108] 2) Preparation of a mixed solution of LipoRNAiMAX (invitrogen) and siRNA: Dilute 10 nM / well siRNA in Table 2 and 1.5 μl of LipoRNAiMAX (invitrogen) in 25 μl serum-free culture medium (Opti-MEM, purchased from Gibco), respectively. Then mix the above siRNA solution with the LipoRNAiMAX (invitrogen) solution and let stand at room temperature for 5 minutes.
[0109] 3) Add 50 μl of the mixed solution of siRNA and LipoRNAiMAX (invitrogen) of the corresponding group to each well.
[0110] 4) After 48 hours of culture, the culture medium was discarded, and the cells were washed twice with enzyme-free PBS, and then lysed with lysis solution (BioFlux). Chloroform (MREDA) was added for extraction. After oscillation and mixing, the cells were allowed to stand at room temperature for 2-3 minutes, centrifuged, and the supernatant after stratification was transferred to a well plate and combined with the binding solution. A nucleic acid extractor was used to arrange the well plates in order according to the instructions of the kit (MagaBio plus Total RNA Purification Kit II, manufacturer Bioer, batch number BSC69L1E), and RNA was extracted using the BSC69 program.
[0111] 5) Prepare the qPCR system on ice, add 1 μl One Step SYBR Green Mix (Novozyme), 10 μl 2*One Step SYBR Green Mix (Novozyme), 0.4 μl hYJH-012 3P F, 0.4 μl hYJH-0123P R to each well, dilute 100 ng RNA in 8.2 μl RNase ddH2O (Novozyme) and add to the wells, mix well and place in a qPCR instrument for reaction.
[0112] PCR reaction conditions: 50°C, 15 min pre-denaturation, 95°C, 1 min, 95°C annealing for 15 s, 60°C extension for 1 min, for 39 cycles.
[0113] PCR Primers:
[0114] hOS-2301 1P F: NF11_140135, 5'-GAGGTCCAAAACGTGTTCTCG-3'
[0115] hOS-2301 1P R: NF11_140136, 5'-ACAGGATGAGGTACACTGGTTG-3'.
[0116] The results are as follows Figure 1As shown, after transfection with LipoRNAiMAX and siRNA mixture, OS-2301-471 sequence had an inhibition rate of 38%, OS-2301-772 sequence had an inhibition rate of 80%, OS-2301-809 sequence had an inhibition rate of 88%, OS-2301-811 sequence had an inhibition rate of 84%, OS-2301-903 sequence had an inhibition rate of 78%, OS-2301-911 sequence had an inhibition rate of 84%, OS-2301-1000 sequence had an inhibition rate of 8 3% inhibition rate, OS-2301-1065 sequence had an inhibition rate of 85%, OS-2301-1071 sequence had an inhibition rate of 59%, OS-2301-1125 sequence had an inhibition rate of 79%, OS-2301-1139 sequence had an inhibition rate of 84%, OS-2301-1467 sequence had an inhibition rate of 85%, OS-2301-2030 sequence had an inhibition rate of 81%, and OS-2301-2051 sequence had an inhibition rate of 78%, and all of them had significant differences.
[0117] Example 4 In vitro experiment on human non-small cell lung cancer cell A549
[0118] The specific steps are as follows:
[0119] 1) Human non-small cell lung cancer cells A549 (purchased from the cell bank of Kunming Institute of Chinese Academy of Sciences) in the logarithmic growth phase were digested with trypsin, and then digestion was terminated with complete medium supplemented with 10% FBS. The cells were collected by centrifugation, resuspended with medium supplemented with 10% FBS, counted with a hemocytometer, and then 25,000 cells were added to each well of a 24-well plate for culture.
[0120] 2) Preparation of LipoRNAiMAX (invitrogen) and siRNA mixture:
[0121] 10 nM / well and 50 nM / well siRNA (OS-2301-1065, OS-2301-1467, OS-2301-2030) and 1.5 μl of LipoRNAiMAX (Invitrogen) were diluted in 25 μl of serum-free culture medium (Opti-MEM, purchased from Gibco), respectively, and then the above siRNA solution was mixed with LipoRNAiMAX (Invitrogen) solution and allowed to stand at room temperature for 5 minutes.
[0122] 3) Add 50 μl of the mixed solution of siRNA and LipoRNAiMAX (invitrogen) of the corresponding group to each well.
[0123] 4) After 48 hours of culture, the culture medium was discarded, and the cells were washed twice with enzyme-free PBS, and then lysed with lysis solution (BioFlux). Chloroform (MREDA) was added for extraction. After oscillation and mixing, the cells were allowed to stand at room temperature for 2-3 minutes, centrifuged, and the supernatant after stratification was transferred to a well plate and combined with the binding solution. A nucleic acid extractor was used to arrange the well plates in order according to the instructions of the kit (MagaBio plus Total RNA Purification Kit II, manufacturer Bioer, batch number BSC69L1E), and RNA was extracted using the BSC69 program.
[0124] 5) Prepare the qPCR system on ice, add 1 μl One Step SYBR Green Mix (Novozyme), 10 μl 2*One Step SYBR Green Mix (Novozyme), 0.4 μl hYJH-012 3P F, 0.4 μl hYJH-0123P R to each well, dilute 100 ng RNA in 8.2 μl RNase ddH2O (Novozyme) and add to the wells, mix well and place in a qPCR instrument for reaction.
[0125] PCR reaction conditions: 50°C, 15 min pre-denaturation, 95°C, 1 min, 95°C annealing for 15 s, 60°C extension for 1 min, for 39 cycles.
[0126] PCR Primers:
[0127] hOS-2301 1P F: NF11_140135, 5'-GAGGTCCAAAACGTGTTCTCG-3'
[0128] hOS-2301 1P R: NF11_140136, 5'-ACAGGATGAGGTACACTGGTTG-3'.
[0129] Novozymes test kit: batch number 7E750A3.
[0130] The results are as follows Figure 2 , Figure 3 As shown, after transfection with the mixture of LipoRNAiMAX and siRNA, at a concentration of 10 nM, the OS-2301-1065 sequence had an inhibition rate of 86%, the OS-2301-1467 sequence had an inhibition rate of 86%, and the OS-2301-2030 sequence had an inhibition rate of 88%. At a concentration of 50 nM, the OS-2301-1065 sequence had an inhibition rate of 84%, the OS-2301-1467 sequence had an inhibition rate of 86%, and the OS-2301-2030 sequence had an inhibition rate of 83%, and there were significant differences.
[0131] Example 5 In vitro experiment on human non-small cell lung cancer cell A549
[0132] The specific steps are as follows:
[0133] 1) Human non-small cell lung cancer cells A549 (purchased from the cell bank of Kunming Institute of Chinese Academy of Sciences) in the logarithmic growth phase were digested with trypsin, and then digestion was terminated with complete medium supplemented with 10% FBS. The cells were collected by centrifugation, resuspended with medium supplemented with 10% FBS, counted with a hemocytometer, and then 25,000 cells were added to each well of a 24-well plate for culture.
[0134] 2) Preparation of LipoRNAiMAX (invitrogen) and siRNA mixture:
[0135] 10 nM / well and 50 nM / well siRNA (Table 3) and 1.5 μl of LipoRNAiMAX (Invitrogen) were diluted in 25 μl of serum-free culture medium (Opti-MEM, purchased from Gibco), and then the above siRNA solution was mixed with LipoRNAiMAX (Invitrogen) solution and allowed to stand at room temperature for 5 minutes.
[0136] 3) Add 50 μl of the mixed solution of siRNA and LipoRNAiMAX (invitrogen) of the corresponding group to each well.
[0137] 4) After 48 hours of culture, the culture medium was discarded, and the cells were washed twice with enzyme-free PBS, and then lysed with lysis solution (BioFlux). Chloroform (MREDA) was added for extraction. After oscillation and mixing, the cells were allowed to stand at room temperature for 2-3 minutes, centrifuged, and the supernatant after stratification was transferred to a well plate and combined with the binding solution. A nucleic acid extractor was used to arrange the well plates in order according to the instructions of the kit (MagaBio plus Total RNA Purification Kit II, manufacturer Bioer, batch number BSC69L1E), and RNA was extracted using the BSC69 program.
[0138] 5) Prepare the qPCR system on ice, add 1 μl One Step SYBR Green Mix (Novozyme), 10 μl 2*One Step SYBR Green Mix (Novozyme), 0.4 μl hYJH-012 3P F, 0.4 μl hYJH-0123P R to each well, dilute 100 ng RNA in 8.2 μl RNase ddH2O (Novozyme) and add to the wells, mix well and place in a qPCR instrument for reaction.
[0139] PCR reaction conditions: 50°C, 15 min pre-denaturation, 95°C, 1 min, 95°C annealing for 15 s, 60°C extension for 1 min, for 39 cycles.
[0140] PCR Primers:
[0141] hOS-2301 1P F: NF11140135, 5'-GAGGTCCAAAACGTGTTCTCG-3'
[0142] hOS-2301 1P R: NF11_140136, 5'-ACAGGATGAGGTACACTGGTTG-3'.
[0143] Novozymes test kit: batch number 7E750A3.
[0144] The results are as follows Figure 4 As shown, the inhibition rate of each sequence is shown in Table 5 below.
[0145] Table 5
[0146] name 10nM average 10nM SD OS-2301-1065 66.0% 3.6% OS-2301-1065mS 86.0% 1.7% OS-2301-1065mE 82.0% 0.0% OS-2301-1467 84.3% 3.2% OS-2301-1467mS 86.7% 1.5% OS-2301-1467mE 86.7% 2.5% OS-2301-2030 81.3% 4.9% OS-2301-2030mS 82.7% 2.5% OS-2301-2030mE 86.3% 6.4%
[0147] As shown in Table 5, the inhibition rates of the six pairs of modified siRNAs can be increased to more than 80%, and the highest inhibition rate can reach 86.7%.
[0148] Example 6 In vitro experiment on human non-small cell lung cancer cell A549
[0149] The specific steps are as follows:
[0150] 1) Human non-small cell lung cancer cells A549 (purchased from the cell bank of Kunming Institute of Chinese Academy of Sciences) in the logarithmic growth phase were digested with trypsin, and then digestion was terminated with complete medium supplemented with 10% FBS. The cells were collected by centrifugation, resuspended with medium supplemented with 10% FBS, counted with a hemocytometer, and then 25,000 cells were added to each well of a 24-well plate for culture.
[0151] 2) Preparation of LipoRNAiMAX (invitrogen) and siRNA mixture:
[0152] 10nM / well and 50nM / well siRNA (OS-2301-1065mS, OS-2301-1467mS, OS-2301-2030mE) and 1.5μl LipoRNAiMAX (Invitrogen) were diluted in 25μl serum-free culture medium (Opti-MEM, purchased from Gibco), respectively, and then the above siRNA solution was mixed with LipoRNAiMAX (Invitrogen) solution and allowed to stand at room temperature for 5 minutes.
[0153] 3) Add 10 μl of the corresponding group of siRNA mixed solution into each well.
[0154] 4) After 48 hours of culture, add 10% volume of CCK8 solution to each well and return to the incubator for further incubation for 2 hours.
[0155] 5) The absorbance of each well at 450 nm was measured using an enzyme-labeled instrument, and the inhibition rate of each group was calculated based on the absorbance of the blank well.
[0156] IC50 of each sequence Figure 5 As shown, the OS-2301-1605mS sequence performed best with an IC50 of 0.14 nM.
[0157] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A siRNA for inhibiting AURKA gene expression, characterized in that: The siRNA contains a sense strand and an antisense strand, and each nucleotide in the siRNA is independently a modified or unmodified nucleotide, wherein the sense strand contains a nucleotide sequence I, and the antisense strand contains a nucleotide sequence II, and the nucleotide sequence I and the nucleotide sequence II are at least partially reverse-complementary to form a double-stranded region, and the nucleotide sequence I and the nucleotide sequence II are selected from any one of the following sequences (a) to (k) and (m) to (n): (a) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.1, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.16, and optionally has no more than 3 nucleotide differences: SEQ ID NO.1: 5'-CAGCAAUUUCCUUGUCAGAAU-3'; SEQ ID NO.16: 5'-UCUGACAGGAAAUUGCUGAG-3'; (b) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.2, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.17, and optionally has no more than 3 nucleotide differences: SEQ ID NO.2: 5'-GGCUUUGGAAGACUUUGAA-3'; SEQ ID NO.17: 5'-UUCAAAGUCUUCCAAAGCC-3'; (c) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.3, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.18, and optionally has no more than 3 nucleotide differences: SEQ ID NO.3: 5'-AGGAAAGUUUGGUAAUGUUUA-3'; SEQ ID NO.18: 5'-AACAUUACCAAACUUUCCUUU-3'; (d) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.4, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.19, and optionally has no more than 3 nucleotide differences: SEQ ID NO.4: 5'-GAAAGUUUGGUAAUGUUUAUU-3'; SEQ ID NO.19: 5'-UAAACAUUACCAAACUUUCCU-3'; (e) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.5, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.20, and optionally has no more than 3 nucleotide differences: SEQ ID NO.5: 5'-GGAGUGGAGCAUCAGCUCAGA-3'; SEQ ID NO.20: 5'-UGAGCUGAUGCUCCACUCCGG-3'; (f) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.6, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.21, and optionally has no more than 3 nucleotide differences: SEQ ID NO.6: 5'-GCAUCAGCUCAGAAGAGAAGU-3'; SEQ ID NO.21: 5'-UUCUCUUCUGAGCUGAUGCUC-3'; (g) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.7, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.22, and optionally has no more than 3 nucleotide differences: SEQ ID NO.7: 5'-GAGUCUACCUAAUUCUGGAAU-3'; SEQ ID NO.22: 5'-UCCAGAAUUAGGUAGACUCUG-3'; (h) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.8, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.23, and optionally has no more than 3 nucleotide differences: SEQ ID NO.8: 5'-AAGUUUGAUGAGCAGAGAACU-3'; SEQ ID NO.23: 5'-UUCUCUGCUCAUCAAACUUUG-3'; (i) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.9, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.24, and optionally has no more than 3 nucleotide differences: SEQ ID NO.9: 5'-GAUGAGCAGAGAACUGCUACU-3'; SEQ ID NO.24: 5'-UAGCAGUUCUCUGCUCAUCAA-3'; (j) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.10, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.25, and optionally has no more than 3 nucleotide differences: SEQ ID NO.10: 5'-UGUCAUUCGAAGAGAGUUAUU-3'; SEQ ID NO.25: 5'-UAACUCUCUUCGAAUGACAGU-3'; (k) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.11, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.26, and optionally has no more than 3 nucleotide differences: SEQ ID NO.11: 5'-AGUUAUUCAUAGAGACAUUAA-3'; SEQ ID NO.26: 5'-AAUGUCUCUAUGAAUAACUCU-3'; (m) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.13, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.28, and optionally has no more than 3 nucleotide differences: SEQ ID NO.13: 5'-UAAAGCUGUUGGAAUGAGUAUGUGA-3'; SEQ ID NO.28: 5'-UCACAUACUCAUUCCAACAGCUUUACC-3'; (n) the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO.14, and optionally has no more than 3 nucleotide differences, and the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO.29, and optionally has no more than 3 nucleotide differences: SEQ ID NO.14: 5'-GUGAUUCUUUUUAAGUAUGAAAAUA-3'; SEQ ID NO. 29: 5'-UAUUUUCAUACUUAAAAAGAAUCACAU-3'.
2. The siRNA according to claim 1, characterized in that At least one nucleotide in the sense strand or the antisense strand is a modified nucleotide.
3. The siRNA according to claim 2, characterized in that At least one nucleotide in the sense strand or the antisense strand is a nucleotide or a nucleotide analogue in which the hydroxyl group at the 2'-position of the ribose group is modified.
4. The siRNA according to claim 3, characterized in that The nucleotide in which the hydroxyl group at the 2' position of the ribose group is modified is selected from a nucleotide modified with 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, T-deoxy-2'-fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-ODMAP), T-O-dimethylaminoethoxyethyl (2'-O-DMAEOE) or 2'-ON-methylacetamide (2'-O-NMA).
5. The siRNA according to claim 3, characterized in that The nucleotide analogue is one of isonucleotide, LNA, ENA, cET BNA, UNA and GNA.
6. The siRNA according to claim 1, characterized in that At least one phosphate group in the sense strand or the antisense strand is a phosphate group having a modified group.
7. The siRNA according to claim 6, characterized in that The phosphate group having a modified group is a thiophosphate group formed by replacing at least one oxygen atom in the phosphodiester bond in the phosphate group with a sulfur atom.
8. The siRNA according to any one of claims 1 to 7, characterized in that The siRNA is selected from the following table: Among them, the lowercase letter m indicates that the ribose group of a nucleotide on the right side of the letter is 2'-methoxyribose; the lowercase letter s indicates that the phosphate groups between the deoxyribonucleotides on both sides of the letter are thiophosphate groups; the lowercase letter f indicates that the ribose group of a nucleotide on the right side of the letter is 2'-O-ribose fluoride-modified.
9. A siRNA conjugate, characterized in that The siRNA conjugate contains the siRNA according to claims 1 to 8 and a conjugated group conjugated to the siRNA; the conjugated group comprises a pharmaceutically acceptable targeting group and a linker, and the siRNA, the linker and the targeting group are sequentially covalently or non-covalently linked.
10. A pharmaceutical composition, characterized in that Contains the siRNA according to any one of claims 1 to 8 and / or the siRNA conjugate according to claim 9 and a pharmaceutically acceptable carrier.
11. Use of the siRNA according to any one of claims 1 to 8, or the siRNA conjugate according to claim 9, or the pharmaceutical composition according to claim 10 in the preparation of a drug for treating a disease caused by AURKA gene expression.
12. Use of the siRNA according to any one of claims 1 to 8, or the siRNA conjugate according to claim 9, or the pharmaceutical composition according to claim 10 in the preparation of a drug for alleviating and / or treating small cell lung cancer.
